Your browser doesn't support javascript.
loading
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
Peters, Solange; Danson, Sarah; Hasan, Baktiar; Dafni, Urania; Reinmuth, Niels; Majem, Margarita; Tournoy, Kurt G; Mark, Michael T; Pless, Miklos; Cobo, Manuel; Rodriguez-Abreu, Delvys; Falchero, Lionel; Moran, Teresa; Ortega Granados, Ana Laura; Monnet, Isabelle; Mohorcic, Katja; Sureda, Bartomeu Massutí; Betticher, Daniel; Demedts, Ingel; Macias, Jose Antionio; Cuffe, Sinead; Luciani, Andrea; Sanchez, Jose Garcia; Curioni-Fontecedro, Alessandra; Gautschi, Oliver; Price, Gillian; Coate, Linda; von Moos, Roger; Zielinski, Christoph; Provencio, Mariano; Menis, Jessica; Ruepp, Barbara; Pochesci, Alessia; Roschitzki-Voser, Heidi; Besse, Benjamin; Rabaglio, Manuela; O'Brien, Mary E R; Stahel, Rolf A.
Afiliación
  • Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch.
  • Danson S; Department of Oncology and Metabolism & Sheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom.
  • Hasan B; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
  • Dafni U; School of Health Sciences, National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece.
  • Reinmuth N; Asklepios Kliniken GmbH, Asklepios Fachkliniken Muenchen, Gauting, Germany.
  • Majem M; Department of Medical Oncology, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain.
  • Tournoy KG; Faculty of Medicine and Life Sciences, Ghent University and Onze-Lieve-Vrouwziekenhuis (OLV), Aalst, Belgium.
  • Mark MT; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Cantonal Hospital Graubuenden, Chur, Switzerland.
  • Pless M; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, Switzerland.
  • Cobo M; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Unidad Gestion Intercentros of Medical Oncology. Regional and Virgen de la Victoria University Hospitals (IBIMA), Málaga, Spain.
  • Rodriguez-Abreu D; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain.
  • Falchero L; Department of Pneumology and Thoracic Oncology, Hopital Nord-Ouest, Villefranche-sur-Saône Cedex, France.
  • Moran T; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, Institut Català d'Oncologia (ICO) Badalona, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona Applied Research Group in Oncology (B-ARGO), Barcelona
  • Ortega Granados AL; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, Hospital Universitario de Jaén, Jaén, Spain.
  • Monnet I; Department of Pneumology, Centre Hopitalier Intercommunal De Créteil, Créteil, France.
  • Mohorcic K; Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia.
  • Sureda BM; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; El Instituto de Investigación Sanitaria y Biomédica de Alicante (SABIAL), Hospital Universitario Alicante, Alicante, Spain.
  • Betticher D; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Fribourg Cantonal Hospital (HFR), Fribourg, Switzerland.
  • Demedts I; Department of Pulmonary Diseases, AZ Delta, Roeselare, Belgium.
  • Macias JA; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Hematology and Oncology, Hospital General Universitario Morales Meseguer, Murcia, Spain.
  • Cuffe S; Cancer Trials Ireland, Dublin, Ireland; Department of Medical Oncology, St. James's Hospital, Dublin, Ireland.
  • Luciani A; Department of Medical Oncology, Ospedale San Paolo, Milano, Italy.
  • Sanchez JG; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, University Hospital Arnau de Vilanova, Valencia, Spain.
  • Curioni-Fontecedro A; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department for Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Gautschi O; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Cantonal Hospital Lucerne, Lucern, Switzerland.
  • Price G; Department of Medical Oncology, Aberdeen Royal Infirmary NHS Grampian, Aberdeen, United Kingdom.
  • Coate L; Cancer Trials Ireland, Dublin, Ireland; Mid-Western Cancer Centre, University Hospital Limerick, Limerick, Ireland.
  • von Moos R; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Department of Medical Oncology, Cantonal Hospital Graubuenden, Chur, Switzerland.
  • Zielinski C; Clinical Division of Oncology, Medical University Vienna, Vienna, Austria; Central European Cooperative Oncology Group, Vienna, Austria.
  • Provencio M; Spanish lung cancer group (Grupo Español de Cancer de Pulmón (GECP)), Barcelona, Spain; Department of Medical Oncology, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain.
  • Menis J; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology Department, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pado
  • Ruepp B; European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Pochesci A; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
  • Roschitzki-Voser H; European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Besse B; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Gustave Roussy Cancer Center Villejuif, Paris Saclay University, Orsay, France.
  • Rabaglio M; European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • O'Brien MER; Department of Medical Oncology, Royal Marsden Hospital, Sutton, United Kingdom.
  • Stahel RA; Department for Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
J Thorac Oncol ; 15(10): 1647-1656, 2020 10.
Article en En | MEDLINE | ID: mdl-32565388
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos